Ryotaro Nakamura, MD
Enriched profileDirector, Center for Stem Cell Transplantation; Professor, Department of Hematology & Hematopoietic Cell Transplantation · City of Hope
Ryotaro Nakamura is Director, Center for Stem Cell Transplantation; Professor, Department of Hematology & Hematopoietic Cell Transplantation at City of Hope. OpenAlex indexes 598 publications with 14,411 citations (h-index 63); ClinicalTrials.gov lists 15 registered studies with this person as an investigator.
Data verified 17 Oct 2026
Overview
Updated 18 Oct 2026
Ryotaro Nakamura, MD, is Director, Center for Stem Cell Transplantation at City of Hope. The public record shows 598 publications with 14,411 citations (h-index 63), centered on Hematopoietic Stem Cell Transplantation, Renal Transplantation Outcomes and Treatments, Transplantation: Methods and Outcomes. It also documents an investigator role on 15 registered clinical trials, industry payments reported by 17 companies, 3 NIH-funded awards (2012–2026).
- Most recent indexed publication: 2026 · Bone marrow transplantation
- Top research focus: Hematopoietic Stem Cell Transplantation
- 15 registered trials on ClinicalTrials.gov
- Open Payments reporting from 17 companies
Generated from the cited public record · current as of 18 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 54 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 192.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 18 Oct 2026
Listed as an investigator on 15 registered studies on ClinicalTrials.gov. The most recent:
- The High Fiber Program to Increase Fiber Intake Among Patients Undergoing Allogeneic Hematopoietic Cell Transplant
Sponsor: City of Hope Medical Center
- BSB-2002 After Cyclophosphamide and Fludarabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation
Sponsor: City of Hope Medical Center
Industry payments
Updated 18 Oct 2026
17 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year20254 payments$11,438openpaymentsdata.cms.gov ↗
- SANOFI US SERVICES INC.Program year20251 payment
- PFIZER INC.Program year20252 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
34.8%Kinase inhibitor19%Jakafi100%Part D<11 patientsCalcineurin inhibitor10.4%Tacrolimus100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
29.9%Corticosteroid20.4%Prednisone100%Part D≥23 patientsProton pump inhibitor9.5%Pantoprazole Sodium100%Part D<11 patientsAnti-infectives
24%Macrolide Antimicrobial9%Azithromycin100%Part D≥13 patientsShort-acting sulfonamides9%Sulfamethoxazole-Trimethoprim100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 18 Oct 2026
3 NIH research awards on record, funded 2012–2026 per NIH RePORTER. The latest:
- CMV-specific CD19 CAR T cells amplified in vivo using CMV Triplex vaccine for B-NHL
Beckman Research Institute/city of Hope
FY2026$738,698R01CA296280 - BMT CTN Core - City of Hope National Medical Center
Beckman Research Institute/city of Hope
FY2026$264,000UG1HL069278 - CMV-specific CD19 CAR T cells amplified in vivo using CMV Triplex vaccine for B-NHL
Beckman Research Institute/city of Hope
FY2025$738,698R01CA296280
Congress activity
Updated 18 Oct 2026
125 congress contributions (2005–2025) across ASCO, ASH, ASTRO per OpenAlex. The most recent:
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 18 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- The 2026 definition of ruxolitinib refractoriness in severe acute GVHD.
Bone marrow transplantation
Letter2026 - Systemic steroid treatment of grade I acute GVHD increases steroid-refractory GVHD and NRM.
Blood immunology & cellular therapy
Article2026 - Long-term survival outcomes of allo-HCT in AML with fludarabine/melphalan conditioning and tacrolimus/sirolimus GVHD prophylaxis.
Bone marrow transplantation
Article2026
Most-cited works
by citation count (OpenAlex)- 01The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal HemoglobinuriaArticle1,303 citations2006
- 02
- 03Hematopoietic Cell TransplantationBook658 citations2015
- 04Ibrutinib for chronic graft-versus-host disease after failure of prior therapyArticle515 citations2017
- 05
Network
Updated 18 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 18 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by others
where others cite or feature them- Other
aamds.org/node/236
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aamds.org ↗ - Other
cancercenter.com/physician-directory/ryotaro-nakamura
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancercenter.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 18 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aamds.org ↗
Editorial & leadership roles
journal and society appointments- Co-chair
Chronic Leukemia Working Committee, Center for International Blood and Marrow Transplant Research
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →aamds.org ↗ - Steering Committee Member
Blood and Marrow Transplant Clinical Trials Network
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →aamds.org ↗ - Director of Community or Clinical Practice
American Society for Transplantation and Cellular Therapy
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →aamds.org ↗
Awards & honors
honors on the public record- Clinical Trial Stage Projects Award
California Institute for Regenerative Medicine ($9,054,216) for treatment of severe aplastic anemia using CD4+ T cell depleted haploidentical donor stem cell transplant
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →aamds.org ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aamds.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Hope Rugo, MD
City of Hope
Jana Portnow, MD
City of Hope
Amandeep Salhotra, MD
City of Hope
Amrita Krishnan, MD
City of Hope
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Jorge Cortes, MD
University of Alabama at Birmingham (UAB)
Ayalew Tefferi, MD
Mayo Clinic
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center